Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 21st, 2026

LECO_Weekly-Healthcare-News_9-21-2026Download

Healthcare Weekly News and Deals –Sept 21st, 2026

  1. CareTrust REIT (NYSE: CTRE) Acquires Southwest Skilled-Nursing Portfolio for $400 Million First public print of a transaction effective September 1. The book is 2,622 licensed SNF beds, triple-net to the incumbent operator with inflation escalators and renewal options. Structured as a joint venture; CareTrust put in about $380 million from cash and settled equity forwards and models an 8.6% stabilized yield. Sourced off-market in markets where both landlord and operator already have scale. Year-to-date deployment is now about $1.9 billion and Q3-to-date about $710 million. Management reloaded the near-term pipeline at about $600 million. (Link)
  2. Lisata Therapeutics (NASD: LSTA) Acquires Marea Therapeutics; $225 Million PIPE Concurrent Stock-for-stock reverse merger plus PIPE. RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive, Sofinnova, Omega, Surveyor/Citadel, Columbia Threadneedle, Nantahala, Affinity, venBio and Rock Springs filled the round. Combined cap table: legacy Lisata about 2.4%, Marea holders about 59.5%, PIPE about 38.1%. Assets are MAR001/005, an ANGPTL4 monoclonal in Phase 2b for severe hypertriglyceridemia, and MAR002, a growth-hormone-receptor antagonist headed to Phase 2 in acromegaly. Runway into 2028; key reads targeted for the fourth quarter of 2027. (Link)
  3. Veracyte (NASD: VCYT) acquires Convergent Genomics for $150 million in cash plus up to $30 million in milestone payments, adding urine-based bladder cancer testing. Veracyte closed its purchase of Convergent Genomics on September 14. It paid $150 million in cash at closing, subject to customary adjustments, with up to $30 million more tied to UroAmp publication and reimbursement milestones. Convergent was founded in 2015 in partnership with Oregon Health & Science University and runs a CLIA-certified lab in South San Francisco. Its UroAmp urinary tumor DNA assay is validated for monitoring therapy response and post-treatment surveillance in non-muscle-invasive bladder cancer. The asset sits alongside Decipher Bladder and TrueMRD, so Veracyte now covers urine, tissue and blood across the bladder cancer pathway. Management expects no material impact on 2026 EBITDA guidance. (Link)
  4. Oaktree commits up to $115 million in milestone-based capital to Saol Therapeutics ahead of the FDA decision date for SL1009. Funds managed by Oaktree will provide up to $115 million to Saol Therapeutics, a private clinical-stage drug company in Roswell, Georgia. An initial tranche funds launch preparation, and the rest is released as regulatory, clinical and commercial milestones are met. The lead drug, SL1009 (sodium dichloroacetate), treats pyruvate dehydrogenase complex deficiency, a rare mitochondrial disease with no approved therapy. The FDA rejected an earlier application in 2025. Saol resubmitted, and the FDA’s decision date is December 30, 2026. Later tranches would fund SL1009 in congenital lactic acidosis and expand SL1002 into more pain indications and spasticity. (Link)
  5. Agora makes a $47 million first investment in Vheda Health, a Columbia, Maryland outcomes and analytics platform for health plans. Agora is a San Francisco private equity firm focused on healthcare technology, founded by Neil Vangala. It has invested $47 million in Vheda Health. This is Agora’s first deal and the first institutional capital in Vheda’s 13-year history. The previously bootstrapped company runs chronic-condition and maternity programs for high-risk Medicaid, Medicare and Special Needs Plan members. It cites more than $975 million in savings for health plan partners and an average 3:1 return on investment. Co-founder and CEO Shameet Luhar stays. The money funds expansion beyond 18 states, new analytics products and targeted acquisitions. (Link)
  6. Ambu (Nasdaq Copenhagen: AMBU B) acquires U.S.-based TIMS Medical (Foresight Imaging) for $45 million upfront plus up to $20 million in milestones to advance its EndoIntelligence platform. Ambu, the Danish single-use endoscopy leader, has bought Foresight Imaging, LLC, which trades as TIMS Medical. It is paying $45 million upfront and up to $20 million in milestones, for total consideration of as much as $65 million. Founded in 2004, TIMS builds hardware and software that record procedure imaging and integrate it into hospital EMR and imaging systems. Its flagship TIMS MVP is widely used in ENT procedures, including FEES exams. The business has about 55 employees, roughly $15 million in annual revenue and around 7,000 installations across U.S. hospitals. Ambu expects the deal to accelerate revenue growth and kept its FY2025/26 outlook unchanged. (Link)
  7. WJRJJ Ventures, owned by Copart (NASD: CPRT) founder Willis Johnson, completes a $40 million private placement in HealthStream (NASD: HSTM). WJRJJ Ventures bought 1.5 million HealthStream shares at $29.50 each. That comprised 1,355,932 new shares for about $40 million and 144,068 existing shares bought from CEO Robert Frist Jr. for about $4.25 million. Frist remains the largest shareholder, with about 16.4%. Johnson, a Nashville-area entrepreneur, was also the first investor in Empath Nursing, founded in 2025. HealthStream sells workforce technology to hospitals and will use the money for product investment and possible acquisitions. (Link)
  8. Arsenal Capital Partners–backed Endpoint Clinical acquires Boston-based Bluefin, a clinical supply forecasting and planning technology provider. Endpoint Clinical, the randomization and trial supply management vendor Arsenal acquired in 2024, has bought Bluefin, a Boston cloud platform for planning clinical supply demand and distribution. The add-on moves Endpoint upstream from RTSM execution into forecasting. Supply plans will link to live enrollment and inventory data, so sponsors can anticipate shifts rather than react to them. Bluefin will keep operating independently and will still connect to competitors’ RTSM systems. Endpoint will add implementation, quality, project management and customer support. Bluefin CEO Andy Maltun stays. (Link)
  9. Seven Hills Capital–backed Spa Medicca of Canton, Ohio acquires Dr. Nicholas E. Sherock LLC & Associates, an Ohio women’s health practice in Massillon and Orrville. Spa Medicca has acquired Dr. Sherock & Associates, a two-location women’s health group in Massillon and Orrville. Dr. Nicholas Sherock leads a five-person clinical team offering gynecologic care, hormone replacement therapy, minimally invasive surgery and aesthetic services. Those services map onto Spa Medicca’s focus on medical aesthetics, hormone optimization and women’s health. The deal adds density in northeast Ohio after earlier work such as Amy Brenner, MD & Associates in Cincinnati. Patients keep existing providers and locations. (Link)
  10. Gauge Capital–backed Reliable Medical acquires Freedom in Mobility and Action Seating & Mobility, expanding CRT coverage across Alabama, Tennessee, Oklahoma, Arkansas and Colorado. Reliable Medical is a Nashville CRT and home medical equipment provider Gauge recapitalized from Seven Hills in January. Freedom in Mobility adds three sites in north Alabama and Tennessee; president Teresa Glass Owens and COO Forrest Owens join. Action Seating & Mobility adds Tulsa, Oklahoma City, Muskogee, Fayetteville, Sherwood and Denver — manual and power chairs, custom seating, ATP-led fitting and repair. Combined network is more than 50 locations. Two add-ons in one week on the same platform. (Link)
  11. NMS Capital launches Asurgence Medical by recapitalizing ENDOCORP and acquiring Medical Optics from Probo Medical. NMS partnered with management to recapitalize Endoscopy Corporation of America of Southfield, Michigan and at the same time bought Medical Optics of Tamarac, Florida from Probo Medical. ENDOCORP supplies more than 15,000 repair-part SKUs for flexible endoscopes. Medical Optics repairs and resells flexible and rigid scopes across manufacturers. Both keep their names as Asurgence subsidiaries. Former Probo CEO Michael Asmer becomes CEO. Thesis is aging equipment fleets and hospital pressure to avoid OEM overhaul pricing. (Link)
  12. Amulet Capital Partners closes a continuation vehicle to recapitalize US Fertility. New and existing investors participated. US Fertility was formed in 2020 and now supports more than 120 clinic and IVF lab locations and over 200 physicians. It has treated more than 400,000 patients. The deal builds on L Catterton’s 2025 entry as co-lead alongside Amulet and the physician partners. Amulet, a healthcare-only sponsor managing about $3.8 billion, stays involved. The new capital funds geographic expansion and clinical innovation. (Link)
  13. Sheridan Capital Partners acquires a majority stake in PtEverywhere, a Raleigh-based practice management and payments platform for physical therapy clinics. Sheridan completed a majority investment in PtEverywhere. The Raleigh platform brings scheduling, clinical documentation, billing and collections into one workflow for small and mid-sized outpatient physical therapy clinics, including cash-pay and hybrid reimbursement models. CEO Andrew Shofner stays. Sheridan plans organic growth and add-ons that broaden the product into adjacent rehab segments. The deal sits next to Sheridan’s 2025 investment in post-acute billing vendor National Care Systems. (Link)
  14. Martis Capital– and Din Ventures–backed Archway Dental Partners acquires Veale Dental, its first Massachusetts practice. Archway Dental Partners, based in Danbury, Connecticut, acquired Veale Dental, a two-location general practice in South Easton and Dartmouth. This is Archway’s first Massachusetts practice and its third acquisition of 2026, after five deals in 2025. The group began as the four-location Dental Associates of Connecticut and now supports more than 40 practices across Connecticut and New York. Entry into a new state rather than an add-on in an existing market. (Link)
  15. Neuberger and KKR (NYSE: KKR) agree to acquire a significant minority stake in Datavant, which remains controlled by New Mountain Capital. Funds managed by Neuberger Capital Solutions and Neuberger Private Markets, together with KKR’s Strategic Investments Group, agreed to buy a significant minority stake in Datavant. New Mountain Capital, an investor since 2014, keeps control. Datavant’s network spans more than 80,000 providers and 75 of the top 100 health systems, and its data touches about 90% of the U.S. population. Growth capital into a scaled asset rather than an exit, funding further digitization and clinical AI. Closing expected in the fourth quarter of 2026. (Link)
  16. Parthenon Capital–backed MRO acquires Vyne Medical from TJC-owned Vyne, adding clinical data intake and document processing. MRO, a Norristown clinical data management platform, acquired Vyne Medical from Vyne, a TJC portfolio company. Vyne Medical turns paper, fax, voice and image inputs into structured data for more than 800 hospitals. Together the companies serve over 2,500 hospitals and 35,000 clinics. Intake tools feed MRO’s medical-records release and data exchange services. Vyne Dental is not part of the deal and stays with TJC. Clean sponsor-to-sponsor handoff. (Link)
  17. NewSpring-, Kineticos-, HealthQuest- and Great Point–backed Kincell Bio Merges with Cellipont to Form Kincellis Advanced Therapies U.S. cell-therapy CDMO combination. Kincell’s immune-cell shop plus Cellipont’s stem, iPSC, MSC, dendritic, exosome and mRNA work. About 140,000 square feet across Gainesville, Research Triangle Park and The Woodlands; 16 qualified GMP suites; more than 150 GMP batches released; 10 INDs this year; 200-plus staff. Darren Head is CEO. Equity led by NewSpring with Kineticos Life Sciences, HealthQuest Capital and Great Point Partners; debt from J.P. Morgan. (Link)
  18. Arlington-Backed Everest Clinical Research Acquires Firma Clinical’s Data Services Unit Toronto data-first CRO buying Firma DS, a biometrics and clinical-data book that has touched more than 1,000 studies and 60-plus NDAs across oncology, neurology, rare disease, hepatology and nephrology. Adds delivery capacity in the U.S. and Asia-Pacific. Firma DS clients get Everest’s full-service stack — regulatory, operations, safety, medical writing — on one CRO. Arlington Capital has owned Everest since 2020. (Link)
  19. Gauge-Backed Rovia Clinical Research Acquires Pinnacle Research Group and Cullman Clinical Trials in Alabama Site-network add-ons on Gauge’s Rovia platform. Pinnacle is an Anniston-area multi-specialty site founded in 1998, with 500-plus completed trials and Phase I capability. Cullman Clinical Trials is its north-central Alabama partner site. The pair gives Rovia owned density in a state it did not previously control. Gauge has funded the site roll-up since the 2024 platform launch. Separate from Reliable Medical, another Gauge healthcare vehicle. (Link)
  20. HealthEdge- and United Western–Backed Veridian Healthcare Acquires ScarScience from Mitchell-Vance Medical-grade silicone scar sheets and gels into plastic surgery, dermatology and physical-therapy channels. Brand add-on onto a wound-and-scar distribution platform rather than a clinic buy. Robert Friedberg remains CEO; Jessica Rowen stays on the seller side of the handoff. HealthEdge Investment Partners and United Western Group are the sponsors. (Link)
  21. Medallion acquires Andros, an NCQA-certified credentials verification organization, creating a credentialing platform covering more than one million providers. Medallion, a San Francisco AI-assisted credentialing and payer-enrollment platform, acquired Andros, an NCQA-certified CVO serving health plans, health systems, provider groups and telehealth companies since 2013. The combination brings more than one million providers across nearly 400 organizations and health plans onto one platform. Andros verifies data on more than 8 million providers and runs about 300,000 credentialing checks a year. Health-plan customers will move onto Medallion’s automated verification tools and AI outreach agents. (Link)
  22. Abry Partners–backed Centauri Health Solutions of Tempe, Arizona acquires Iowa-based Benny the Benefits Navigator to expand its SSI/SSDI eligibility technology. Centauri acquired Benny the Benefits Navigator, an Iowa startup founded in 2024 by Jeremy Shapiro, James Vancel and Joel Segre. Its AI platform replaces paper forms with a conversational digital intake for SSI and SSDI applications. Benny folds into Centauri’s Member Connect disability eligibility service, which already reaches more than 60 million lives. Latest add-on under Abry after the 2025 MedAllies purchase. (Link)
  23. Ignitus Recovery acquires AIM Health Boulder, a Colorado mental health and substance-use treatment program for young adults. Englewood-based Ignitus acquired AIM Health Boulder, a 20-year Boulder program treating adults 18–30 through PHP and IOP at the historic Earl House. Ignitus plans to keep existing programs and add residential treatment, alumni engagement and long-term recovery support. Founder Danny Conroy said he chose Ignitus to carry the program forward. CEO Steve Millette committed to no disruption for clients, staff or referral partners. (Link)
  24. Stony Brook Medicine Community Medical Group acquires South Shore Digestive Medicine, a Bay Shore, New York gastroenterology practice led by Dr. Darius Sorbi. The community physician arm of Stony Brook Medicine acquired South Shore Digestive Medicine in Bay Shore. Dr. Darius Sorbi trained in internal medicine at Stony Brook and completed his GI fellowship at Mayo Clinic. He specializes in advanced endoscopy, biliary and pancreatic disease and GI cancers. The practice is now listed at 10 Brentwood Road, Bay Shore, alongside Stony Brook GI sites in Commack and Lake Grove. Extends the SUNY-owned academic system’s coverage onto Long Island’s South Shore. (Link)
  25. AKTIV Against Cancer Merges with CancerFit Exercise-oncology combination. AKTIV is the U.S. sister of Norway’s Aktiv mot kreft — hospital gyms branded Pusterom in Norway and AKTIVcenter in the U.S., research funding at Memorial Sloan Kettering, first U.S. site at Summit Health in New Jersey. CancerFit is the digital and program counterpart. No price and no cap table on the open wire. Merger of two mission-aligned exercise-as-treatment platforms, not a clinic roll-up. (Link)
  26. Daia Orthodontics & TMJ Orthopedics acquires four former docbraces clinics in New Brunswick and Prince Edward Island, its first expansion outside the U.S. Rochester Hills, Michigan-based Daia acquired four clinics that previously operated under the docbraces name, in Grand Falls and Woodstock, New Brunswick, and Charlottetown and Summerside, Prince Edward Island. The founder-owned practice goes from one location to five. Founder Dr. Hadi Daia is certified in both the U.S. and Canada and has treated patients at these clinics since 2021, converting an existing clinical relationship into ownership. Current clinical and administrative teams stay. No outside sponsor was named. (Link)
  27. Medartis Holding (SIX: MED) Acquires M.A.R.C. Institute in Doral, Florida First permanent training site outside Europe and the group’s largest, with 36 surgical stations and capacity for 140 participants. Name and general manager Heloise Peixoto stay; the IBRA partnership continues; universities, societies and other device companies keep access. Satellite activity in São Paulo, Rio and Curitiba. Osteosynthesis implant maker buying education infrastructure, not a clinic roll-up. (Link)
  28. Xenetic Biosciences (NASD: XBIO) to Acquire Santersus AG in an All-Stock Exchange; Combined Company to Be Santersus Bio Agreement dated September 14, public print September 16. Swiss NucleoCapture blood-purification device plus Xenetic’s DNase platform against neutrophil extracellular traps. Santersus holders about 85%, Xenetic about 15% on a fully diluted basis. Pipeline includes Breakthrough Device-designated work in sepsis and SLE. Combined company expected to trade as Santersus Bio. Close targeted in the fourth quarter on a stockholder vote and Nasdaq listing of new shares. (Link)

Venture Deals and Other

  1. Vitruvian Partners leads Angle Health’s $600 million financing at a $2.7 billion valuation, with Town Hall Ventures, Blumberg Capital, Portage Ventures, Prudential Financial (NYSE: PRU)’s PruVen Capital and Y Combinator participating. London-based Vitruvian Partners led a $600 million equity financing in Angle Health at a headline $2.7 billion valuation. It combines a $200 million Series C with a $400 million tender offer for existing shareholders. New investor Town Hall Ventures joined existing backers Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The San Francisco company provides AI-driven health benefits to more than 5,000 small and mid-sized employers, with nearly $1 billion in annualized premiums. It reports 120% growth and four profitable quarters in a row. (Link)
  2. Thoreau leads a $100 million funding commitment to Penelope Health, with Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp participating. Thoreau, the healthcare investment platform led by former New Mountain Capital president Matt Holt, has committed $100 million to London-based Penelope Health. Existing backers Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp joined. The funding comes with a partnership to build shared infrastructure for real-time payments and clinical coverage rules. Penelope’s platform tracks insurer coverage policies for more than 200 million Americans across over 15,000 procedure and drug codes. The amount is a commitment rather than a closed round. (Link)
  3. JMI Equity leads Archy’s $50 million Series C, with TCV, Entrée Capital, Bessemer Venture Partners, CRV and Alven participating. JMI Equity led a $50 million Series C in Archy, a San Jose AI platform for running dental practices. Existing investors TCV, Entrée Capital, Bessemer, CRV and Alven joined. Total funding now stands at $97 million. Built-in AI agents handle claims and collections, visit notes, insurance eligibility, patient communications and analytics. Archy serves more than 1,000 practices in 45 states and processes over $300 million in payments a year. (Link)
  4. Catalio Capital Management leads AVAVA’s $45 million financing, made up of $30 million in equity and a $15 million debt facility. Catalio, AVAVA’s first institutional investor, led a $45 million package of $30 million in equity and a $15 million debt facility. The relationship includes $10 million of growth capital from Catalio’s Structured Opportunities Fund in 2024. Boston-based AVAVA sells aesthetic laser devices built on Focal Point Technology, which delivers energy to targeted depths in the skin. The money funds commercial expansion, new products and international growth. (Link)
  5. Obvious Ventures leads Mithrl’s $20 million Series A, with Headline and AGI House participating. Obvious Ventures led a $20 million Series A in Mithrl, a California company building AI infrastructure for drug developers. Headline, AGI House and several pharma executives participated. Its second-generation platform, Mithrl-1, pairs a proprietary biomedical model with agents that choose models and manage cost. It runs inside each client’s environment. The company says top-10 pharma companies and clinical-stage biotechs already use it, with a goal of 50% faster IND timelines. (Link)
  6. Neon leads Ayble Health’s $16 million Series A, with Unum Group (NYSE: UNM)’s Unum Ventures, Upfront Ventures, M13, Ohio-based Cleveland Clinic Ventures, DigiTx and Accomplice participating. Neon led an oversubscribed $16 million Series A in Boston-based Ayble Health. Total capital raised now exceeds $27 million. Ayble runs an AI-enabled virtual clinic for digestive conditions, sold to national health plans, large employers and benefit platforms. It reports a 47% average improvement in symptoms and at least a 3:1 return for customers. The money strengthens AI care tools and expands the company into autoimmune conditions. (Link)
  7. GOA Therapeutics Emerges from Stealth with $15.5 Million; Unveils GOA26 for Acute Alcohol Intoxication Dallas preclinical shop. In an IND-enabling porcine model after 1.2 g/kg oral ethanol, blood alcohol concentration was 61.3% lower versus control at 20 minutes. No FDA-approved drug rapidly lowers BAC today. IND targeted by year-end 2026; first-in-human work in 2027. Data were presented the same day at AAST in Dallas. (Link)
  8. Khosla Ventures leads Nara Health’s $14 million pre-seed and seed financing, with Long Journey Ventures and Superior Studios participating. Khosla led $14 million across pre-seed and seed in Nara Health, formerly Avant Health. Long Journey Ventures, Superior Studios and angels joined. The Chicago company administers health plans for self-insured employers using AI — benefits, claims, care coordination and member support. Nara has more than 25,000 members and has processed over $600 million in claims. CEO Sid Sinha said the money funds Chicago hiring and platform scale. (Link)
  9. Flare Capital Partners leads Kairon Health’s $5 million round, with Tau Ventures, Lightbank, General Advance and Pave Health Ventures participating. Flare led a $5 million round in Kairon Health, joined by Tau Ventures and existing backers Lightbank, General Advance and Pave Health Ventures. Founder Nick Bartz spent nine years at Aledade. The New York AI platform turns claims, records, admission alerts, lab and pharmacy data into task lists for staff at ACOs, health systems and physician groups. It covers more than one million patients across 30-plus states under Medicare, Medicaid and commercial value-based contracts. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)